It reduces tumor growth and microvessel density in a ras-dependent/VEGF-independent tumor model [249], in syngeneic and xenograft gliomas [247], in orthotopic bladder cancer [244] and ovarian carcinoma xenografts [246] and in Lewis lung carcinoma [245]. The gene discussed is VEGFA; the disease is neoplasm.